Real-world study of JAK inhibitor medicines for alopecia areata
Looks at how well JAK inhibitors work and their safety in alopecia areata.
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 29 Jul 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 6 groups
- Treatments tested
- Tofacitinib
- Baricitinib
- Ruxolitinib
- Upadacitinib
- Abrocitinib
- Ritlecitinib
- Record updated
- 27 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with alopecia areata (patchy hair loss) who have been treated with a JAK inhibitor medicine for more than 3 months.
- Age
- The criteria say 2 to 18 years old. The record also lists an age range of 2 Years to 80 Years.
- Sex
- All sexes can join.
- Disease stage
- Alopecia areata diagnosed according to the AA guideline.
- Earlier treatment
- Must have been treated for more than 3 months with a JAK inhibitor: tofacitinib, baricitinib, ritlecitinib, abrocitinib, upadacitinib or ifidancitinib.
Main reasons for not taking part
- Hair implants received before
- Another type of hair loss
- Other diseases that can cause hair loss, such as psoriasis or lichen planus
- Hair loss score (SALT score) cannot be measured at the start or at follow-up
- Taking part in other clinical trials
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib for more than 3 months
Who cannot take part
- Patients had previously received hair implants
- Other diseases may induce alopecia including psoriasis, lichen planus, et al
- Other alopecia
- Unable to estimate SALT score at baseline or at follow-up
- Patients are participating in other clinical trials
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 2 and 80 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib,abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.
The 6 groups in the trial
- Tofacitinib treated group
In the real-world settings, patients with AA treated with tofacitinib.
Treatment: Tofacitinib
- Baritinib treated group
In the real-world settings, patients with AA treated with baritinib.
Treatment: Baricitinib
- Ruxolitinib treated group
In the real-world settings, patients with AA treated with ruxolitinib
Treatment: Ruxolitinib
- Upadacitinib treated group
In the real-world settings, patients with AA treated with upadacitinib.
Treatment: Upadacitinib
- Abrocitinib treated group
In the real-world settings, patients with AA treated with abhicitinib.
Treatment: Abrocitinib
- Ritlecitinib treated group
In the real-world settings, patients with AA treated with ritlecitinib.
Treatment: Ritlecitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
- Plain-language title
- Real-world study of JAK inhibitor medicines for alopecia areataGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06573593, who can take part
- Record updated
- 27 August 2024